15 States Forge Alliance to Advance Ibogaine Treatment, Sharing costs and risks in bipartisan effort to combat mental health crisis
Representatives from 15 states developed a working model for multistate collaboration on ibogaine clinical research during the first-ever Aspen Ibogaine Meeting (AIM) in Colorado, according to an AIM news release.
The model prioritizes cost sharing, risk reduction and a more efficient path to clinical development. By pooling resources and coordinating efforts, participating states aim to harmonize state-led clinical initiatives under a common effort to ensure safety and efficacy and minimize risk, AIM stated in the news release.
The proposed framework ensures that states that help fund the research will have early access to future treatment programs when ibogaine therapy gains approval. If successful, this strategy could serve as a blueprint for financing additional research into ibogaine’s potential to treat a range of mental health and neurological conditions, AIM said.
The private, invitation-only event took place over three days and included legislators, researchers, regulators and public health officials.
Representatives from Mexico, Canada and Gabon were also in attendance.
The meeting marked a rare and historic moment of bipartisan cooperation and cross-sector alignment, according to the AIM news release.
“This was more than just a meeting,” said Bryan Hubbard, executive director of AIM and co-organizer of the Aspen Ibogaine Meeting. “It was the beginning of a movement. Leaders from across the country are coming together to say: we must do better—and ibogaine may be one of the most promising tools we have to change the future trajectory of the American
The next Aspen Ibogaine Meeting (AIM) will take place in late October 2025. State leaders interested in attending can email AIM@ACSMedia.org for more information.